Italia markets closed

Qiagen N.V. (0RLT.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
46,94+1,24 (+2,71%)
Alla chiusura: 06:45PM BST
Schermo intero
Chiusura precedente45,70
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno45,65 - 47,21
Intervallo di 52 settimane45,65 - 47,21
Media VolumeN/D
Beta (5 anni mensile)0,42
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    QIAGEN N.V. to release results for Q3 2023 and hold webcast

    Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 Lon

  • GlobeNewswire

    QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus

    QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosisVenlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Q

  • GlobeNewswire

    QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness

    AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence f